Premium
Comparison of local therapy in patients with lung oligo‐recurrence of non‐small‐cell lung cancer
Author(s) -
Sonoda Dai,
Matsuura Yosuke,
Kondo Yasuto,
Ichinose Junji,
Nakao Masayuki,
Ninomiya Hironori,
Nishio Makoto,
Okumura Sakae,
Satoh Yukitoshi,
Mun Mingyon
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26453
Subject(s) - medicine , lung cancer , radiation therapy , lung , surgery
Background and Objectives The effectiveness of local therapy has been reported in non‐small‐cell lung cancer (NSCLC) patients with oligo‐recurrence. However, there is still no clear consensus on the choice of local therapy. We aimed to examine the choice of local therapy in NSCLC patients with lung oligo‐recurrence. Methods Among 1760 consecutive NSCLC patients who underwent complete resection between 1990 and 2008, 535 patients developed recurrence. Lung oligo‐recurrence was defined as 1–5 metachronous recurrences limited to the lungs only; such recurrence was found in 97 patients. We examined the differences in the prognosis of each therapy for these patients. Results The 5‐year postrecurrence survival (PRS) rates in patients who underwent local therapy ( n = 54) and those who did not ( n = 43) were 55.6% and 31.1%, respectively; it was significantly higher in patients who underwent local therapy ( p = 0.004). Among 47 patients who underwent resection or radiation therapy, the 5‐year PRS rates were 61.5% and 47.6% ( p = 0.258), and the 5‐year postrecurrence progression‐free survival rates were 30.3% and 24.7% ( p = 0.665), respectively, without any significant difference. Conclusions Patients with lung oligo‐recurrence should consider local therapy individually, depending on their general condition.